Department of Vermont Health Access  
Pharmacy Benefits Management Program  
*DUR Board Meeting Agenda*

January 20th, 2015  6:00 – 8:30 p.m.

1. **Executive Session**  6:00 - 6:45  
   - Orientation presentation -GHS  
   - Discussion on Medicaid OBRA'90/Supplemental Rebates and Agreements  
     (as provided by 33 VSA § 1998(f)(2))

2. **Introductions and Approval of DUR Board Minutes**  6:45 - 6:45  
   (Public Comment Prior to Board Action)

3. **DVHA Pharmacy Administration Updates**  6:45 - 6:50  
   - Updates

4. **Medical Director Update**  6:50 - 6:55  
   - Clinical Programs Update  
   - Prescriber Comments

5. **GHS Presentation on Clinical/Reading Materials**  6:55-7:00

6. **Follow-up Items from Previous Meetings**  7:00-7:20  
   - Vivitrol step-through for Opiate Dependence  
   - Zohydro ER new formulation

7. **RetroDUR/DUR**  7:20 – 7:20  
   None this meeting

8. **Clinical Update: Drug Reviews**  7:20 – 7:45  
   (Public comment prior to Board action)  
   **Abbreviated New Drug Reviews-None**

**Full New Drug Reviews**
- Entyvio (vedolizumab) 300mg single-dose vial  
- Jublia (efinaconazole) 10% topical solution  
- Sivextro (tedizolid) 200 mg tablet  
- Tanzeum (albiglutide) for injection  
- Harvoni (90 mg ledipasvir and 400 mg sofosbuvir) tablet  
- Viekira pak (ombitasvir, paritaprevir, and ritonavir tablet, dasabuvir tablet)  
- Zohydro ER (hydrocodone bitartrate) extended-release capsules

9. **Therapeutic Drug Classes – Periodic Review**  7:45 – 7:55  
   - (Public comment prior to Board action)  
   Sublingual Immunotherapy
10. New Managed Therapeutic Drug Classes 7:55 – 7:55
(Public comment prior to Board action)
  ▪ None

11. Review of Newly-Developed/Revised 7:55 – 8:25
Clinical Coverage Criteria and/or Preferred Products
(Public comment prior to Board action)
  ▪ Hepatitis C update and recommendations
    o Sovaldi
    o Harvoni
    o Viekira Pak

12. General Announcements 8:25– 8:30
Selected FDA Safety Alerts
  o FDA recommends not using lidocaine to treat teething pain and requires new Boxed
    Warning (6/26/2014) http://www.fda.gov/drugs/drugsafety/ucm402240.htm
  o Methylphenidate HCl ER tablets (generic Concerta) made by Mallinckrodt and Kudco:
    FDA concerns about therapeutic equivalence with 2 generic versions of Concerta tablets
    (11/13/2014) http://www.fda.gov/drugs/drugsafety/ucm422568.htm
  o FDA reviews long-term antiplatelet therapy as preliminary trial data shows benefits but a
    higher risk of non-cardiovascular death (11/16/2014)
    http://www.fda.gov/Drugs/DrugSafety/ucm423079.htm
  o FDA warns about case of rare brain infection PML with MS drug Tecfidera (dimethyl
  o FDA issues final rule on changes to pregnancy and lactation labeling information for
    prescription drug and biological products 12/3/2014)
    http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm425317.htm
  o FDA reporting mental health drug ziprasidone (Geodon) associated with rare but
    potentially fatal skin reaction (12/11/2014)
    http://www.fda.gov/Drugs/DrugSafety/ucm426391.htm
  o FDA has reviewed possible risks of pain medicine use during pregnancy (1/9/2015)
    http://www.fda.gov/Drugs/DrugSafety/ucm429117.htm

13. Adjourn 8:30